Source: SEC

Volastra received $15M in Equity Funding

Followers on Owler

Est. Annual Revenue

$5.0-25M

Est. Employees

1-25

CEO

Charles Hugh-Jones

CEO Approval Rating

86/100

Volastra is a New York-based clinical-stage biotechnology company that researches and develops novel therapies for the treatment of cancer.